AeroVanc (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. Vancomycin, administered by injection into a vein (also called intravenous or IV administration), is the antibiotic of choice for MRSA-related bronchopneumonia, however, the inconvenience of IV administration, poor penetration into the lungs and systemic toxicities limit its use in a chronic setting. By delivering vancomycin directly to the site of infection in the lungs, the hope is that AeroVanc will improve clinical efficacy and reduce adverse effects due to systemic drug exposure. AeroVanc has been granted orphan drug status (link) by the U.S. Food and Drug Administration (FDA).

Go to summary


Molgradex® is Savara’s proprietary, nebulized formulation of recombinant human GM-CSF. GM-CSF is short for granulocyte-macrophage colony-stimulating factor and is a naturally occurring protein in the human body. Molgradex is being developed for the treatment of patients with pulmonary alveolar proteinosis (PAP). Savara is working to demonstrate that inhalation of GM-CSF as a facilitator of a positive immune response will modify the course of PAP and reduce or eliminate the need for whole lung lavage. Savara has patented the use of recombinant human GM-CSF administered via inhalation and Molgradex has been granted orphan drug status by European Medicines Agency (EMA).

Go to summary


Alveodex is Savara’s proprietary nebulized formulation of Factor VIIa (recombinant human FVIIa) –  a protein that occurs naturally in the body and plays a central and important role in the coagulation cascade. Alveodex is being developed for the treatment of patients suffering from diffuse alveolar hemorrhage (DAH) and other high-risk patient populations within respiratory diseases in a critical-care setting.

Go to summary


Back to Top